



Methods: Participants received placebo or combination treatment with perindopril and indapamide.

Results: Over 4.3 years of follow-up, there was a significant reduction in major macrovascular or microvascular events with perindopril and indapamide compared with placebo. In addition, the relative risk of death from cardiovascular disease was reduced by 18% (3.8% with combination treatment versus 4.6% with placebo), and the relative risk of all-cause mortality was reduced by 14% (7.3% with combination treatment versus 8.5% with placebo).



Average BP:
136/72 mm Hg

Average BP:
140/73 mm Hg



Reference: Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007;370(9590):829-840. [www.thelancet.com/journals/lancet/article/PIIS0140-6736\(07\)61303-8](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61303-8).